GlassScriptPhysician profile
Jeffrey C Hoschek
NPI 1376641217
$5,455.04
in general payments reported to CMS, 2019-2025
44 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $654 · 2021: $614 · 2022: $905 · 2023: $1,290 · 2024: $1,016 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,895.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $764.07 | 2019-2025 | |
| Novo Nordisk INC | $724.71 | 2019-2025 | Wegovy, Ozempic |
| Pfizer INC. | $422.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $400.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $305.40 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $263.72 | 2019-2023 | Seglentis, Livalo |
| Janssen Pharmaceuticals, INC | $241.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $201.49 | 2019-2023 | Gardasil 9, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $170.56 | 2022-2024 | |
| Inspire Medical Systems, INC. | $165.23 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $159.84 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $156.14 | 2021-2024 | Jardiance, Mounjaro |
| Abbott Laboratories | $144.64 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Dexcom, INC. | $142.75 | 2023-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $116.88 | 2020-2023 | Austedo |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hoschek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.